[A24-68] Ublituximab (multiple sclerosis) – Addendum to Project A24-13
Last updated 01.08.2024
Project no.:
A24-68
Commission:
Commission awarded on 11.06.2024 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Indication:
Adults with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features
Result of dossier assessment:
- Men who have not yet received disease-modifying therapy and show no evidence of a severe course of disease: proof of considerable added benefit
- Women who have not yet received disease-modifying therapy and show no evidence of a severe course of disease: added benefit not proven
- Patients who have not yet received disease-modifying therapy and show evidence of a severe course of disease and adults who show an active course of disease despite treatment with a disease-modifying therapy: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
DOI:
https://doi.org/10.60584/A24-68_en
| Project no. | Title | Status |
|---|---|---|
| A24-13 | Ublituximab (multiple sclerosis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
01-08-2024 A G-BA decision was published.
G-BA documents on this decision